Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray
Immune activation and several autoantibodies might be involved in the pathophysiology of irritable bowel syndrome (IBS). We aimed to identify serum biomarkers for IBS by HuProt™ microarray. IBS patients met Rome III criteria were enrolled. Control groups included healthy controls (HCs) and disease c...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.1010069/full |
| _version_ | 1818024469782855680 |
|---|---|
| author | Wenjuan Fan Wenjuan Fan Xiucai Fang Chaojun Hu Guijun Fei Qiyun Xiao Yongzhe Li Yongzhe Li Xiaoqing Li Jackie D. Wood Xuan Zhang |
| author_facet | Wenjuan Fan Wenjuan Fan Xiucai Fang Chaojun Hu Guijun Fei Qiyun Xiao Yongzhe Li Yongzhe Li Xiaoqing Li Jackie D. Wood Xuan Zhang |
| author_sort | Wenjuan Fan |
| collection | DOAJ |
| description | Immune activation and several autoantibodies might be involved in the pathophysiology of irritable bowel syndrome (IBS). We aimed to identify serum biomarkers for IBS by HuProt™ microarray. IBS patients met Rome III criteria were enrolled. Control groups included healthy controls (HCs) and disease controls (DCs). In stage I, we profiled sera from IBS and control groups with HuProt™ microarrays. Based on significant different proteins in stage I, IBS focused microarrays were constructed and validated in a larger cohort in stage II, then decision tree models were generated to establish a combination of biomarkers. In stage III, 4 purified proteins were verified by ELISA. Finally, we analyzed the correlation of autoantibodies with symptoms. In stage I, we identified 47 significant different proteins including 8 autoantibodies of IgG, 2 of IgA between IBS and HCs; 13 autoantibodies of IgG, 13 of IgA between IBS and DCs. In stage II, we found the positive rates of 14 IgG and IgA autoantibodies in IBS were significantly higher than HCs. Five autoantibodies of IgG and 7 IgA were comprehensively involved in differentiating IBS and HCs with the sensitivity and specificity to diagnose IBS as 40%–46.7% and 79.4%–86.3%. The median optical density value of ELAVL4 (IgG) and PIGP (IgA) were significantly higher in IBS than HCs. Parts of autoantibodies above were related to IBS symptoms. We found a combination of autoantibodies to differentiate IBS with HCs, but no specific autoantibodies could serve as serum biomarkers for IBS. |
| first_indexed | 2024-12-10T04:00:43Z |
| format | Article |
| id | doaj.art-10ccc7e8263e4510914092c3297c39a8 |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-10T04:00:43Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-10ccc7e8263e4510914092c3297c39a82022-12-22T02:02:58ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2022-10-011310.3389/fphys.2022.10100691010069Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarrayWenjuan Fan0Wenjuan Fan1Xiucai Fang2Chaojun Hu3Guijun Fei4Qiyun Xiao5Yongzhe Li6Yongzhe Li7Xiaoqing Li8Jackie D. Wood9Xuan Zhang10Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Rheumatology and Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Physiology and Cell Biology, Wexner Medical Center, The Ohio State University, Columbus, OH, United StatesDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaImmune activation and several autoantibodies might be involved in the pathophysiology of irritable bowel syndrome (IBS). We aimed to identify serum biomarkers for IBS by HuProt™ microarray. IBS patients met Rome III criteria were enrolled. Control groups included healthy controls (HCs) and disease controls (DCs). In stage I, we profiled sera from IBS and control groups with HuProt™ microarrays. Based on significant different proteins in stage I, IBS focused microarrays were constructed and validated in a larger cohort in stage II, then decision tree models were generated to establish a combination of biomarkers. In stage III, 4 purified proteins were verified by ELISA. Finally, we analyzed the correlation of autoantibodies with symptoms. In stage I, we identified 47 significant different proteins including 8 autoantibodies of IgG, 2 of IgA between IBS and HCs; 13 autoantibodies of IgG, 13 of IgA between IBS and DCs. In stage II, we found the positive rates of 14 IgG and IgA autoantibodies in IBS were significantly higher than HCs. Five autoantibodies of IgG and 7 IgA were comprehensively involved in differentiating IBS and HCs with the sensitivity and specificity to diagnose IBS as 40%–46.7% and 79.4%–86.3%. The median optical density value of ELAVL4 (IgG) and PIGP (IgA) were significantly higher in IBS than HCs. Parts of autoantibodies above were related to IBS symptoms. We found a combination of autoantibodies to differentiate IBS with HCs, but no specific autoantibodies could serve as serum biomarkers for IBS.https://www.frontiersin.org/articles/10.3389/fphys.2022.1010069/fullirritable bowel syndromebiomarkersautoantibodiesautoimmunityHuProtTM microarrays |
| spellingShingle | Wenjuan Fan Wenjuan Fan Xiucai Fang Chaojun Hu Guijun Fei Qiyun Xiao Yongzhe Li Yongzhe Li Xiaoqing Li Jackie D. Wood Xuan Zhang Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray Frontiers in Physiology irritable bowel syndrome biomarkers autoantibodies autoimmunity HuProtTM microarrays |
| title | Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray |
| title_full | Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray |
| title_fullStr | Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray |
| title_full_unstemmed | Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray |
| title_short | Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray |
| title_sort | multiple rather than specific autoantibodies were identified in irritable bowel syndrome with huprot™ proteome microarray |
| topic | irritable bowel syndrome biomarkers autoantibodies autoimmunity HuProtTM microarrays |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2022.1010069/full |
| work_keys_str_mv | AT wenjuanfan multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT wenjuanfan multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT xiucaifang multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT chaojunhu multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT guijunfei multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT qiyunxiao multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT yongzheli multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT yongzheli multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT xiaoqingli multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT jackiedwood multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray AT xuanzhang multipleratherthanspecificautoantibodieswereidentifiedinirritablebowelsyndromewithhuprotproteomemicroarray |